| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.24 | 4e-08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.24 | 4e-07 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-07 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.21 | 5e-05 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |